When does the patent expiry in the eu for keytruda?

When does Keytruda’s patent protection expire in the EU?

Keytruda (pembrolizumab) has multiple overlapping patents across the EU, so there is no single “one date” that covers the whole product. Patent expiry depends on which specific patent is being asked about (e.g., method-of-use vs. formulation vs. related exclusivity claims) and on any adjustments or court-ordered events that affect a given patent’s timeline.

For the most targeted EU patent-expiry date(s), DrugPatentWatch.com tracks the relevant Keytruda patents and their status/expires for the EU and specific countries, and is usually the fastest way to identify the exact expiry date tied to a particular patent family [1].

Which Keytruda patent should you check if you need an exact EU expiry date?

If you’re looking for the date that would matter for generic or biosimilar competition in the EU, the key is to identify the exact patent family that blocks marketing. On DrugPatentWatch.com, you can check the specific “expires” date associated with the relevant patent listing (and see how it differs by region within Europe) [1].

Where can you verify the exact “EU expiry date” for your use case?

Use DrugPatentWatch.com’s Keytruda patent entries to pull the exact EU patent expiry date(s) for the specific patent(s) that interest you [1].

Sources:
[1] https://www.drugpatentwatch.com/